Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Mar 27, 2024 12:22pm
291 Views
Post# 35955751

A rock-solid BTD application.

A rock-solid BTD application.If you look on the regulatory timeline on page 14 of the last Corporate Presentation 03,19,2024.
You will see that the '' Health Canada and FDA marketing approval is projected for end of 2026''.

In this link...
https://journals.lww.com/oncology-times/toc/2021/11050
Click on '' Rethinking FDA's Breakthrough Designation''
Second paragraph...
It is said'' BTD has shortened the time from submission to approval for oncology therapy by a median of 2.3 years compared to products without BTD''.

Let's see...
Dec 2026-2.3 years= Sept/Oct 2024.
TLT is still ahead of a normal BTD approval timeline by a few months.

I prefer that TLT take its time and do not make any major mistake in its BTD application.
A good exemple of a company that wanted to go to fast is ImmunityBio(N-803+BCG).
In 2021 ImmunityBio SP was at $40.00 ,then ImmunityBio started making mistake and the SP droped by 90%...Note; ImmunityBio is being sued by investors for ignoring Good Manufacturing Practice.

A word of advice to TLT...
Take your time and give the FDA a rock-solid BTD application.
If you do...we will all win.



<< Previous
Bullboard Posts
Next >>